OSI Pharmaceuticals, Patent Term Extension for Tarceva(R) (erlotinib)

Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that the Company has received Notice of Final Determination from the US Patent and Trademark Office that the patent for Tarceva(R) (erlotinib), US Patent No. 5,747,498, covering composition of matter, processes for its preparation, methods of treating cancer, and pharmaceutical compositions containing Tarceva has been extended through November 8, 2018. In addition to the composition of matter patent, OSI also has a crystalline polymorph patent (US Patent No. 6,900,221) for Tarceva which expires in 2020... OSI Pharmaceuticals' Press Release -